Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
143
resultados
Última actualización
25/04/2025 [06:59:00]
Resultados 75 a 100 de 143
Resumen de: JP2024169624A
To provide a method for inspecting ulcerative colitis which is useful for determining a disease state of ulcerative colitis.SOLUTION: A method for producing a strain sample derived from a subject in which the strain diversity and/or the number of strains in the sample of the subject are maintained includes: 1) a process of adding the sample of the subject to a culture medium; 2) a process of performing an operation to bring pH of the culture medium to 6.2 to 6.7 in starting the cultivation if necessary; and 3) a process of culturing the sample after starting the cultivation without performing an operation intended to maintain pH of the culture medium. Preferably, the method includes A) a process of performing sterilization of the culture medium and aeration to anaerobic gas and/or B) a process of suspending the sample to ascorbic acid-added phosphate buffer, before 1).SELECTED DRAWING: Figure 1
Resumen de: US2024400694A1
Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.
Resumen de: WO2023141097A1
Disclosed are methods for treating active eosinophilic colitis (EoC), or in certain aspects, inflammatory bowel disease (IBD), in an individual in need thereof. In one aspect, the methods may comprise a) assaying a tissue sample obtained from a colon of an individual who may be in need of such treatment, wherein the assaying comprises detecting expression of one or more gene of a transcriptome gene set; b) calculating a score based on the expression of one or more gene of a transcriptome gene set; and c) selecting a tissue sample that exhibits a score indicative of EoC or IBD. The methods may further comprise administering an EoC or IBD therapy to the individual whose tissue sample exhibited a score indicative of having EoC or IBD.
Resumen de: CN119061137A
The invention discloses an eRNA molecular marker for auxiliary diagnosis of Crohn's disease and application of the eRNA molecular marker, and is characterized in that the eRNA molecular marker is eRNA42767, and the nucleotide sequence of the eRNA molecular marker is shown as SEQ ID NO.1. The invention also provides application of the eRNA molecular marker in preparation of a kit for auxiliary diagnosis of Crohn's disease, and the kit comprises an eRNA42767 fluorescent quantitative PCR specific amplification primer, the nucleotide sequence of the upstream amplification primer is 5 '-CCTCTCTCTGGACATGCCTA-3', and the nucleotide sequence of the downstream amplification primer is 5 '-CCTATGCGTAGAGATTCTTGCC-3'. The kit has the advantages that early diagnosis of a patient suffering from the Crohn disease on the molecular level is conveniently, quickly and efficiently realized, the pertinence is strong, the specificity is strong, the sensitivity is high, and the kit is beneficial to early discovery and timely treatment of the Crohn disease.
Resumen de: CN119061105A
The invention discloses a research method for promoting ulcerative colitis barrier repair mechanism by using butyric acid to activate intestinal epithelial autophagy, and relates to the field of digestive systems.The research method comprises the following steps that S1, a clinical sample is collected and analyzed; s2, animal model construction and experiment; s3, carrying out cell experiment verification; according to the research method for promoting the barrier repair mechanism of ulcerative colitis by activating intestinal epithelial autophagy through butyric acid, the influence of butyric acid on intestinal epithelial autophagy and barrier functions in UC patients and animal models is systematically researched, the new mechanism of promoting UC barrier repair by activating ATG16L1 related autophagy pathways through butyric acid is disclosed, a new theoretical basis is provided for UC treatment, and the research method has wide application prospects. By deeply researching the regulation and control mechanism of butyric acid on ATG16L1 related autophagy, accurate diagnosis and personalized treatment of UC can be realized, that is, a proper treatment scheme is selected according to the specific condition of a patient, so that the treatment effect is improved, and the unnecessary medical expenditure is reduced.
Resumen de: CN119039421A
The invention discloses a CLDN-10b spliceosome polypeptide as shown in SEQ ID: 1, a CLDN-10b mutant polypeptide as shown in SEQ ID: 2, an antibody capture device containing the polypeptides as shown in SEQ ID: 1 and SEQ ID: 2, a kit and a detection method, and belongs to the technical field of immunology. According to the technical scheme, CLND-10b polypeptide containing SEQ ID: 1 and SEQ ID: 2 is cloned and expressed, an antibody in a sample is captured through a solid-phase carrier and the polypeptide contained on the solid-phase carrier, and the effect of auxiliary diagnosis of the inflammatory bowel disease-psoriasis co-disease is achieved.
Resumen de: US2024395384A1
Provided are systems and methods for treating an immune-mediated inflammatory disease (e.g., inflammatory bowel disease) in a subject or selecting the subject for treatment, based on an estimated time to remission following induction of an anti-TNF therapy calculated by a patient-centric precision model.
Resumen de: AU2023276693A1
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
Resumen de: WO2024240709A1
The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: US2024393333A1
This invention is directed to compositions and methods to detect and treat gastrointestinal diseases.
Resumen de: US2024392374A1
The invention relates to diagnostic and therapeutic methods for inflammatory bowel disease. Disclosed is a method of differentiating between ulcerative colitis (UC) and Crohn's disease (CD) in a subject having an inflammatory bowel disease (IBD) comprising determining a level of one or more of SEQ ID NOs: 1-590 in a sample from the subject.
Resumen de: US2024389885A1
Described herein are methods of utilizing single fasting methane breath concentrations to monitor, select treatment for, and to treat subjects having intestinal methanogen overgrowth.
Resumen de: US2024392375A1
The invention relates to diagnostic and therapeutic methods for inflammatory bowel disease (IBD).
Resumen de: US2024391994A1
The present disclosure is generally relates to methods of treating ulcerative colitis. The methods are particularly suitable for treating bowel urgency a specific sub-group of patients with ulcerative colitis and having bowel urgency.
Resumen de: CN118995910A
The invention relates to application of Terrisporobacter spp as a marker in a product for assisting in predicting the curative effect of VDZ on ulcerative colitis, and belongs to the technical field of molecular biomedicine. The invention provides Terrisporobacter spp, and application of Terrisporobacter spp as a marker in a product for assisting in predicting the curative effect of VDZ on ulcerative colitis. According to the application, Terrisporobacter spp is selected as the marker for predicting the curative effect of treating UC by VDZ, UC patients can be distinguished to be sensitive to VDZ and not sensitive to VDZ, early diagnosis is conducted on VDZ sensitive patients, and the application has the advantages of being high in accuracy and sensitivity.
Resumen de: WO2024236584A1
Methods of diagnosing inflammatory bowel disease (IBD), ulcerative colitis (UC) or Crohn's disease (CD) in a subject in need thereof, comprising receiving a stool sample from the subject and measuring DNA levels in the stool sample are provided. Kits comprising at least one reagent that detects mammalian DNA and not bacterial DNA and at least one reagent that detects cell type-specific DNA methylation are also provided.
Resumen de: WO2024239006A1
The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
Resumen de: US2024384349A1
The invention relates to the identification of biomarkers of the response status of a patient for a treatment with anti-TNFalpha agents, for treatment with anti-α4β7 agents or with both anti-TNFalpha agent and anti-α4β7 agents and to their use in assessing such status, in particular for assessing nonresponsive status for a treatment with anti-TNFalpha agents or respectively with anti-α4β7 agent in human patients suffering from inflammatory condition or disease, in particular Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis or Crohn's disease. The invention describes a method of in vitro assessing whether a treatment with anti-TNFalpha agent or with with anti-α4β7 agent may be useful in a human suffering from inflammatory condition or disease, in particular when said condition or disease is a chronic and/or relapsing one, particularly a gastrointestinal, more particularly intestinal, inflammatory condition or disease which is eligible for treatment with anti-TNFalpha agent or respectively with anti-α4β7 agent.
Resumen de: US2024383882A1
The present invention discloses a number of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.
Resumen de: ES2988838A1
Method to predict the response of Crohn's disease patients to anti-TNF-α therapy based on plasma levels of vinculin together with the Crohn's disease activity index (CDAI), corticosteroid induction and bowel resection. (Machine-translation by Google Translate, not legally binding)
Resumen de: CN118979093A
The invention relates to the technical field of poultry pathogenic bacterium detection, in particular to a detection culture medium, a preparation method of the detection culture medium, a kit and a method for detecting chicken necrotic enteritis by applying the detection culture medium. The invention discloses a detection culture medium, a preparation method of the detection culture medium, a kit and a method for detecting chicken necrotic enteritis by using the detection culture medium. The content of clostridium perfringens in the excrement sample is judged according to the color change degree and the color change time, and then the infection degree of the chicken necrotic enteritis is obtained. Therefore, the method can be used for rapid detection on a breeding site, and has a wide application prospect.
Resumen de: US2024376210A1
A method for treating a human patient suffering from fistulizing Crohn's disease, comprising administering to a patient suffering from fistulizing Crohn's disease, a humanized antibody having binding specificity for human α4β7 integrin, wherein the human patient has a seton that was surgically placed prior to administration of the antibody, and wherein the dosing regimen induces fistula (e) healing.
Resumen de: MX2020013157A
Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P<sub>1</sub>) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (<i>R</i>)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1, 2,3,4-tetrahydrocyclopenta<i>b</i>indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
Resumen de: CN118957046A
The invention belongs to the technical field of medicine preparation, and particularly relates to an intestinal injury and intestinal flora protection method which comprises the following specific operation steps: S1, experimental sample selection and grouping: selecting 360 1-day-old specific pathogen-free SPF white leghorns for an experiment, randomly dividing the white leghorns into 6 groups, repeating 6 in each group, and selecting a sample; according to the application, a chicken in-vivo salmonella infection model is constructed, various data indexes are integrated, the effect is optimal when the puerarin dosage is 100mg/kg, the puerarin has a protection effect on salmonella challenge, the growth performance of chickens can be improved, the damage of intestinal epithelial villus is improved, the anti-inflammatory effect is exerted, and the immune system of the body is protected. In addition, microbe 16S rRNA analysis finds that puerarin can resist inflammation and damage induced by salmonella by adjusting intestinal flora. Research results of the application show that puerarin has potential in the aspects of replacing antibiotics to control salmonella infection in poultry production and improving food safety.
Nº publicación: US2024376210A1 14/11/2024
Solicitante:
TAKEDA PHARMACEUTICAL COMPANY LTD [JP]
Takeda Pharmaceutical Company Limited
Resumen de: US2024376210A1
A method for treating a human patient suffering from fistulizing Crohn's disease, comprising administering to a patient suffering from fistulizing Crohn's disease, a humanized antibody having binding specificity for human α4β7 integrin, wherein the human patient has a seton that was surgically placed prior to administration of the antibody, and wherein the dosing regimen induces fistula (e) healing.
BOPI
Sede Electrónica
